Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment.
2008
219
LTM Revenue $37.0M
LTM EBITDA -$5.2M
$1.4B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Gubra has a last 12-month revenue of $37.0M and a last 12-month EBITDA of -$5.2M.
In the most recent fiscal year, Gubra achieved revenue of $28.6M and an EBITDA of -$3.9M.
Gubra expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Gubra valuation multiples based on analyst estimatesFY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $27.9M | $28.6M | $35.8M | $37.0M | XXX |
Gross Profit | $23.2M | $13.7M | $16.1M | XXX | XXX |
Gross Margin | 83% | 48% | 45% | XXX | XXX |
EBITDA | $2.0M | -$3.9M | -$5.2M | -$5.2M | XXX |
EBITDA Margin | 7% | -14% | -15% | -14% | XXX |
Net Profit | $9.5M | $0.6M | -$6.2M | XXX | XXX |
Net Margin | 34% | 2% | -17% | XXX | XXX |
Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 7, 2025, Gubra's stock price is DKK 628 (or $88).
Gubra has current market cap of DKK 10.2B (or $1.4B), and EV of DKK 9.9B (or $1.4B).
See Gubra trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$1.4B | $1.4B | XXX | XXX | XXX | XXX | $-0.21 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 7, 2025, Gubra has market cap of $1.4B and EV of $1.4B.
Gubra's trades at 37.3x LTM EV/Revenue multiple, and -265.9x LTM EBITDA.
Analysts estimate Gubra's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Gubra and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $1.4B | XXX | XXX | XXX |
EV/Revenue | 38.6x | XXX | XXX | XXX |
EV/EBITDA | -263.6x | XXX | XXX | XXX |
P/E | -281.7x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | -449.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGubra's NTM/LTM revenue growth is 33%
Gubra's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Gubra's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Gubra's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Gubra and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 25% | XXX | XXX | XXX | XXX |
EBITDA Margin | -15% | XXX | XXX | XXX | XXX |
EBITDA Growth | 34% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | 18% | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 44% | XXX | XXX | XXX | XXX |
Opex to Revenue | 79% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Gubra acquired XXX companies to date.
Last acquisition by Gubra was XXXXXXXX, XXXXX XXXXX XXXXXX . Gubra acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Gubra founded? | Gubra was founded in 2008. |
Where is Gubra headquartered? | Gubra is headquartered in Denmark. |
How many employees does Gubra have? | As of today, Gubra has 219 employees. |
Is Gubra publicy listed? | Yes, Gubra is a public company listed on CSE. |
What is the stock symbol of Gubra? | Gubra trades under GUBRA ticker. |
When did Gubra go public? | Gubra went public in 2023. |
Who are competitors of Gubra? | Similar companies to Gubra include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
What is the current market cap of Gubra? | Gubra's current market cap is $1.4B |
What is the current revenue of Gubra? | Gubra's last 12-month revenue is $37.0M. |
What is the current EBITDA of Gubra? | Gubra's last 12-month EBITDA is -$5.2M. |
What is the current EV/Revenue multiple of Gubra? | Current revenue multiple of Gubra is 37.3x. |
What is the current EV/EBITDA multiple of Gubra? | Current EBITDA multiple of Gubra is -265.9x. |
What is the current revenue growth of Gubra? | Gubra revenue growth between 2023 and 2024 was 25%. |
Is Gubra profitable? | Yes, Gubra is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.